Summary & Overview
HCPCS Level II J0608: Lanthanum Carbonate Oral Powder, 5 mg
HCPCS Level II code J0608 denotes lanthanum carbonate oral powder, 5 mg, a phosphate binder formulation used to manage hyperphosphatemia in patients such as those with end-stage renal disease on dialysis. Nationally, this code matters for pharmacy benefit administration, specialty drug coverage, and dialysis care cost management because oral phosphate binders are commonly prescribed chronic therapies with implications for medication adherence and payer pharmacy spend.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for phosphate-binding therapy, typical sites of service for dispensing and use, and what to expect in payer coverage patterns. The publication also summarizes benchmark considerations and policy updates relevant to drug coding and reimbursement for orally administered, non-equivalent formulations.
This report provides benchmarks where available, highlights payer coverage themes, and explains clinical and billing context for coding and claims processing for J0608. Data not available in the input is indicated where applicable.
Billing Code Overview
HCPCS Level II code J0608 represents lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to J0607. This product is an oral phosphate binder formulation used in the management of hyperphosphatemia, commonly among patients with end-stage renal disease on dialysis and other conditions requiring phosphate control.
Service type: Prescription oral medication therapy for phosphate binding.
Typical site of service: Outpatient pharmacy dispensing and administration for outpatient or dialysis clinic use. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with end-stage renal disease (ESRD) who is being managed for hyperphosphatemia. The patient is receiving outpatient dialysis care and has persistent hyperphosphatemia despite dietary phosphate restriction and first-line phosphate binders. The nephrologist prescribes oral lanthanum carbonate powder J0608 as a non-calcium, non-aluminum phosphate binder to reduce serum phosphate levels. The clinical workflow includes medication counseling by the prescribing provider or dialysis nurse, verification of the correct product and dose on the medication administration record, documentation of administration or dispensing, monitoring of serum phosphorus at regular intervals, assessment for gastrointestinal side effects, and coordination with outpatient pharmacy for home dosing. Prior authorization may be required by some payors; documentation typically includes a diagnosis of chronic kidney disease or ESRD with hyperphosphatemia, prior treatment history, current serum phosphate values, and the prescribing nephrologist’s rationale for lanthanum carbonate use.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Not typically appended; used when no other modifier applies |